Associated tags: Patient, Canadian Aviation Regulations, Therapy, Cancer, SAN, Pharmaceutical industry, CD22, CAR, MD, CD19, Doctor of Philosophy, Research, B-cell lymphoma
Locations: EUROPE, EUROPEAN UNION, NEW YORK, RUSSELL, SAN MATEO, CA, US, TD, NEW YORK CITY, CR, CAR
Retrieved on:
Tuesday, October 17, 2023
University,
Stanford Cancer Institute,
Antibody,
Monoclonal antibody,
Division,
Drug,
Research,
Trial of the century,
Stanford University School of Medicine,
MD,
Mosunetuzumab,
BLA,
IND,
Health,
Biotechnology,
Medicine,
Disease,
Cancer,
Patient,
BA,
Therapy,
B-cell lymphoma,
CAR,
NME,
CD22,
Publication,
SAN,
CD19,
BMT,
Acceleration,
Baylor University,
B Division (New York City Subway),
NIH,
Pharmaceutical industry,
Nursing,
Stanford University,
Blood SAN MATEO, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CARGO), a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the appointment of Ginna Laport, MD, as Chief Medical Officer. Dr. Laport is a seasoned biotechnology executive and senior clinical leader. She will serve on the Company’s executive team and will be responsible for providing leadership and direction to guide CARGO’s clinical development strategy and execution, including the advancement of CARGO’s lead candidate, CRG-022, as well as its pipeline of next-generation CAR T-cell therapies for cancer patients. CRG-022 is an autologous CD22 chimeric antigen receptor (CAR) T-cell therapy candidate, currently in a potentially pivotal Phase 2 clinical trial in patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy.
Key Points:
- SAN MATEO, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CARGO), a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the appointment of Ginna Laport, MD, as Chief Medical Officer.
- “We are thrilled to announce the addition of Ginna to our team as Chief Medical Officer.
- With her extensive leadership background in clinical drug development, particularly in hematology/oncology, she brings invaluable expertise to our organization,” said Gina Chapman, CARGO’s President and Chief Executive Officer.
- Previously, Dr. Laport was Chief Medical Officer at Tempest Therapeutics, where she directed the clinical development of small molecules that combine both tumor-targeted and immune-mediated mechanisms, including several IND submissions.
Retrieved on:
Tuesday, September 12, 2023
Lymphoma,
Juno,
Gilead Sciences,
BS,
University,
B-cell lymphoma,
Therapy,
Multiple myeloma,
Netherlands Cancer Institute,
Cancer,
Janssen,
Fred Hutchinson Cancer Research Center,
University of California,
Research,
Bristol Myers Squibb,
Doctor of Philosophy,
CAR,
Developmental Biology (journal),
Documentation,
Patient,
SAN,
Celgene,
European,
Janssen Pharmaceuticals,
Cell,
Juno Therapeutics,
BLA,
IND,
Pharmaceutical industry SAN MATEO, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CARGO), a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the appointment of Michael Ports, PhD, as Chief Scientific Officer. Dr. Ports will be responsible for advancing CARGO's proprietary platform technologies and discovery-stage programs.
Key Points:
- SAN MATEO, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CARGO), a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the appointment of Michael Ports, PhD, as Chief Scientific Officer.
- “I am delighted to welcome Michael, an experienced leader in cell therapy, to CARGO as our Chief Scientific Officer.
- Michael brings strong scientific leadership and a deep understanding of cell therapy to this role and will be an inspiring thought partner to our research and development teams,” said Gina Chapman, CARGO's President and Chief Executive Officer.
- Throughout my career, I have sought opportunities to develop differentiated therapeutics and treatment strategies to significantly improve outcomes for patients,” said Michael Ports, Chief Scientific Officer, CARGO Therapeutics.
Retrieved on:
Thursday, August 24, 2023
Doctor of Pharmacy,
Pediatrics,
CD19,
Independent,
Stanford University,
Biotechnology,
Cancer,
Independent director,
Bristol Myers Squibb,
Genentech,
Sutro Biopharma,
Audit committee,
CAR,
MD,
Patient,
Celgene,
Series,
Drug discovery,
Rhône-Poulenc,
Entrepreneurship,
Johnson & Johnson,
BMS,
Therapy,
Management,
Pharmaceutical industry,
Medicine SAN MATEO, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CARGO), a clinical-stage biotechnology company uniquely positioned to advance next generation CAR T-cell therapies designed to provide hope for a cure for more cancer patients, today announced the addition of independent directors to the Board of Directors following its recent $200 million Series A financing in March 2023. The Board brings together an esteemed group of experienced life science leaders with expertise spanning finance, business operations, drug discovery and clinical development, including experts and pioneers in CAR T-cell therapies and oncology.
Key Points:
- The Board brings together an esteemed group of experienced life science leaders with expertise spanning finance, business operations, drug discovery and clinical development, including experts and pioneers in CAR T-cell therapies and oncology.
- The most recent board appointments include John Orwin as Chairman of the Board, David Lubner as Independent Director and Strategic Finance and Audit Committee Chair, and Krishnan Viswanadhan, PharmD, as Independent Director.
- During his time at BMS, he oversaw the teams responsible for the development, approval and life cycle management of commercial CAR T therapies.
- Additional members of the CARGO Board of Directors are listed below; full bios are available on the CARGO website .
SAN MATEO, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CARGO), a biotechnology company advancing a next generation of CAR T-cell therapies for cancer, today announced that management will present at the upcoming Jefferies Global Healthcare Conference on Friday, June 9, 2023 at 9:00 a.m. Eastern Time in New York City.
Key Points:
- SAN MATEO, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CARGO), a biotechnology company advancing a next generation of CAR T-cell therapies for cancer, today announced that management will present at the upcoming Jefferies Global Healthcare Conference on Friday, June 9, 2023 at 9:00 a.m. Eastern Time in New York City.
- CARGO is advancing an autologous CD22 chimeric antigen receptor (CAR) T-cell therapy as well as a pipeline of next generation CAR T-cell therapies for cancer using its proprietary cell engineering platform technologies.
- The Company's lead clinical candidate, CRG-022, is preparing to enter a pivotal Phase 2 clinical trial in 2023.
Janus,
B-ALL,
Disease resistance,
JD,
Transplant,
Therapy,
Safety,
Doctor of Philosophy,
Cancer,
MD,
Survival,
Leukapheresis,
Crystal Mackall,
Breakthrough therapy,
CD19,
Disease,
CAR,
Engineering,
Nex Entertainment,
B-cell lymphoma,
FDA,
Patient,
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
Cellular,
ORR,
T. Rowe Price,
CD22,
Third Rock Ventures,
LP,
Canadian Aviation Regulations,
Emerson Collective,
Investment,
Wellington Management Company,
CR,
RTW,
Food,
Financial services,
Pharmaceutical industry,
Vaccine,
Blood SAN MATEO, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CARGO), a biotechnology company advancing a next generation of CAR T-cell therapies for cancer, today announced the close of a $200 million oversubscribed and upsized Series A financing. The financing was co-led by Third Rock Ventures, RTW Investments, LP and Perceptive Xontogeny Venture Fund, and includes additional new investors Nextech, Janus Henderson Investors, Ally Bridge Group, Wellington Management, funds and accounts advised by T. Rowe Price Associates, Inc., Cormorant Asset Management and Piper Heartland. Founding investor Samsara BioCapital and existing seed investors Red Tree Venture Capital and Emerson Collective also participated in the financing. CARGO is advancing what will potentially be a first and best-in-class autologous CD22 chimeric antigen receptor T-cell (CAR T) therapy as well as a pipeline of next generation CAR T-cell therapies for cancer using its proprietary cell engineering platform technologies.
Key Points:
- Founding investor Samsara BioCapital and existing seed investors Red Tree Venture Capital and Emerson Collective also participated in the financing.
- CARGO also intends to advance its proprietary platform technologies and discovery-stage programs to deliver better outcomes for patients with cancer who have high unmet need.
- CARGO Therapeutics is building upon deep expertise in understanding resistance to CAR T-cell therapies to deliver next generation cell products for patients,” said Gina Chapman, CEO of CARGO Therapeutics.
- The founders' overarching mission was to overcome CAR resistance to extend the clinical benefit of CARs for patients in need.
